SFA Therapeutics

SFA Therapeutics, formerly known as SFA Therapeutics, Inc., operates out of Philadelphia, PA, with a team of four employees. The company is part of the healthcare industry, specifically focusing on therapeutics. They are known for their innovative approach in the clinical development of treatments for a wide range of diseases such as autoimmune diseases, infectious diseases, liver diseases, dermatology, ophthalmology, and oncology. Their pipeline includes treatments for conditions like Psoriasis, Liver Cancer (including Hepatitis B, NASH, and HCC), Ophthalmic Diseases, Cytokine Release Syndrome, and the prevention of relapse/recurrence in leukemias. SFA Therapeutics aims to revolutionize treatment by creating safer, therapeutically-tailored oral drugs that regulate the immune system. These drugs are derived from bacterial metabolites and are designed to block the root cause of many chronic inflammatory diseases. The company’s focus on microbiome-derived drugs highlights their commitment to leveraging natural substances to provide safer alternatives to current therapies. SFA Therapeutics was part of the Y-Combinator S21 batch and serves regions including the United States of America, America/Canada, and offers remote and partly remote working options.